Scientific rationale: Combining imiquimod and surgical treatments for basal cell carcinomas

Journal of Drugs in Dermatology

Volumn 7, Issue 1, 2008, Pages

  Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT;

BASAL CELL CARCINOMA; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; SCAR; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CICATRIX; COMBINED MODALITY THERAPY; HUMANS; SKIN NEOPLASMS;

EID: 40349111059     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14. (Pubitemid 29097684)
2. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MYD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200. (Pubitemid 34141451)
3. Cornell R, Greenway HT, Tucker SB. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990;23:694.
4. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol. 2003;149(S66):59-61. (Pubitemid 38064522)
5. Geisse JK, Chakrabarty A. Efficacy and safety of imiquimod 5% cream in the treatment of superficial basal cell carcinoma. J Am Acad Dermatol. 2004;50:722-733.
6. Suhge d'Aubermont PC, Bennett RG. Failure of curettage and electrodessication for removal of Basal Cell Carcinoma. Arch Dermatol. 1984;120:1456-1460.
7. Carrasco D, Straten M, Tyring SK. Treatment of anogenital warts with imiquimod 5% cream. J Am Acad Dermatol. 2002;47:S212-216.
8. Berman B, Flores F: Interferons. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA:WB Saunders; 2001:339-357.
9. Saed GM, Ladin D, Olson J, Han X, Hou Z, Fivenson D. Analysis of p53 Gene Mutations in Keloids using polymerase chain reaction-based single-strand conformation polymorphism and DNA sequencing. Arch Dermatol. 1998;134:963-967. (Pubitemid 28385318)
10. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon-α2b Injections. J Am Acad Dermatol. 1997;37(5 Pt 1):755-757. (Pubitemid 27500320)
11. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002;47(suppl):S209-211.
12. Berman B, Frankel S, Villa AM, Ramirez CC, Poochareon V, Nouri K. Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. Dermatol Surg. 2005;31:1399-1403.
13. Prado A, Andrades P, Benitez S, Umaña M. Scar management after breast surgery: preliminary results of a prospective, randomized, and double-blind clinical study with aldara cream 5% (imiquimod). Plast Reconstr Surg. 2005;115:966-972. (Pubitemid 40316466)
14. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32:63-69.